Toxicity and antitumor activity of novel agents in elderly patients with cancer included in phase 1 studies.
Antitumor activity
Early-phase clinical trials
Elderly population
Geriatric comorbidities
Journal
Investigational new drugs
ISSN: 1573-0646
Titre abrégé: Invest New Drugs
Pays: United States
ID NLM: 8309330
Informations de publication
Date de publication:
12 2021
12 2021
Historique:
received:
01
05
2021
accepted:
12
07
2021
pubmed:
22
7
2021
medline:
17
2
2022
entrez:
21
7
2021
Statut:
ppublish
Résumé
Introduction The number of cancer cases among the elderly continue to increase as the worldwide population ages. This patient subset is underrepresented in clinical trials, partly because of unresolved uncertainties about age-associated tolerabilities and antitumor activities. We reviewed phase 1 trial data to study tolerance and efficacy of novel agents used for treatment of elderly patients with cancer. Methods Data from 773 consecutive evaluable patients in 85 phase 1 clinical trials (2008-2016) at START Madrid-CIOCC were analyzed according to age, with respect to objective response, survival, and toxicity. Results The mean age was 58.7 (range: 18-87) years; 260 (33.6%) patients were >65 y (elderly group). One hundred thirty-seven (17.8%) patients received immunotherapy drugs, 308 (39.8%) received targeted agents, and 328 (42.4%) received chemotherapy. No statistically significant differences in overall survival, objective response, or severe toxicity rates were found according to treatment type. Similar toxicities and clinical activities were found between the two age subgroups; 18.8% of the elderly and 20.7% of the younger patients experienced severe hematological toxicity (p=0.5), and 30.2% and 32.7%, respectively, experienced severe non-hematological toxicity (p=0.4). Regarding antitumor activity, 12.4% of the elderly and 15% of the younger patients achieved objective responses (p=0.41). There were no significant between-group differences in overall survival (9.7 versus 11.5 months, respectively, p=0.1) or progression-free survival (2.3 versus 2.2 months, respectively, p=0.7). Conclusions This retrospective study found that elderly and younger populations had comparable antitumor activities and toxicity profiles. These results support including elderly patients with cancer in early-phase trials.
Identifiants
pubmed: 34287771
doi: 10.1007/s10637-021-01150-1
pii: 10.1007/s10637-021-01150-1
doi:
Substances chimiques
Antineoplastic Agents
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1694-1701Informations de copyright
© 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Références
Altekruse SF, Kosary CL, Krapcho M, Neyman N, Aminou R, Waldron W et al (2009) SEER Cancer Statistics Review, 1975-2007, National Cancer Institute. Bethesda, MD, https://www.seer.cancer.gov/csr/1975_2007/ , based on November 2009 SEER data submission, posted to the SEER web site, 2010
White MC, Holman DM, Boehm JE et al (2014) Age and cancer risk: A potentially modifiable relationship. Am J Prev Med 46:1–16. https://doi.org/10.1016/j.amepre.2013.10.029
doi: 10.1016/j.amepre.2013.10.029
Henley SJ, Ward EM, Scott S et al (2020) Annual report to the nation on the status of cancer, part I: National cancer statistics. Cancer 126:2225–2249. https://doi.org/10.1002/cncr.32802
doi: 10.1002/cncr.32802
pubmed: 32162336
Finkel T, Serrano M, Blasco MA (2007) The common biology of cancer and ageing. Nature 448:767–774. https://doi.org/10.1038/nature05985
doi: 10.1038/nature05985
pubmed: 17700693
Arciero VS, Cheng S, Mason R et al (2018) Do older and younger patients derive similar survival benefits from novel oncology drugs? A systematic review and meta-analysis. Age Ageing 47:654–660. https://doi.org/10.1093/ageing/afy079
doi: 10.1093/ageing/afy079
pubmed: 29788041
Shenoy P, Harugeri A (2015) Elderly patients’ participation in clinical trials. Perspect Clin Res 6:184–189. https://doi.org/10.4103/2229-3485.167099
doi: 10.4103/2229-3485.167099
pubmed: 26623388
pmcid: 4640010
Quoix E, Zalcman G, Oster JP et al (2011) Carboplatin and weekly paclitaxel doublet chemotherapy compared with monotherapy in elderly patients with advanced non-small-cell lung cancer: IFCT-0501 randomised, phase 3 trial. Lancet (London, England) 378:1079–1088. https://doi.org/10.1016/S0140-6736(11)60780-0
doi: 10.1016/S0140-6736(11)60780-0
LoConte NK, Smith M, Alberti D et al (2010) Amongst eligible patients, age and comorbidity do not predict for dose-limiting toxicity from phase I chemotherapy. Cancer Chemother Pharmacol 65:775–780. https://doi.org/10.1007/s00280-009-1084-8
doi: 10.1007/s00280-009-1084-8
pubmed: 19649630
Javid SH, Unger JM, Gralow JR et al (2012) A prospective analysis of the influence of older age on physician and patient decision-making when considering enrollment in breast cancer clinical trials (SWOG S0316). Oncologist 17:1180–1190. https://doi.org/10.1634/theoncologist.2011-0384
doi: 10.1634/theoncologist.2011-0384
pubmed: 22723506
pmcid: 3448411
Fang P, He W, Gomez DR et al (2017) Influence of Age on Guideline-Concordant Cancer Care for Elderly Patients in the United States. Int J Radiat Oncol Biol Phys 98:748–757. https://doi.org/10.1016/j.ijrobp.2017.01.228
doi: 10.1016/j.ijrobp.2017.01.228
pubmed: 28366580
pmcid: 5504701
Townsley CA, Chan KK, Pond GR et al (2006) Understanding the attitudes of the elderly towards enrolment into cancer clinical trials. BMC Cancer 6:1–9. https://doi.org/10.1186/1471-2407-6-34
doi: 10.1186/1471-2407-6-34
Townsley CA, Naidoo K, Pond GR et al (2003) Are older cancer patients being referred to oncologists? A mail questionnaire of Ontario primary care practitioners to evaluate their referral patterns. J Clin Oncol Off J Am Soc Clin Oncol 21:4627–4635. https://doi.org/10.1200/JCO.2003.06.073
doi: 10.1200/JCO.2003.06.073
Kemeny MM, Peterson BL, Kornblith AB et al (2003) Barriers to clinical trial participation by older women with breast cancer. J Clin Oncol Off J Am Soc Clin Oncol 21:2268–2275. https://doi.org/10.1200/JCO.2003.09.124
doi: 10.1200/JCO.2003.09.124
Siu LL, Shepherd FA, Murray N et al (1996) Influence of age on the treatment of limited-stage small-cell lung cancer. J Clin Oncol Off J Am Soc Clin Oncol 14:821–828. https://doi.org/10.1200/JCO.1996.14.3.821
doi: 10.1200/JCO.1996.14.3.821
Takuwa H, Tsuji W, Yotsumoto F (2018) Overall survival of elderly patients with breast cancer is not related to breast-cancer specific survival: A single institution experience in Japan. Breast Dis 37:177–183. https://doi.org/10.3233/BD-170280
doi: 10.3233/BD-170280
pubmed: 29660894
Olver I (2000) Chemotherapy for elderly patients with advanced cancer: is it worth it? Aust Prescr 23:80–82. https://doi.org/10.18773/austprescr.2000.090
Greil R (1998) Prognosis and management strategies of lymphatic neoplasias in the elderly. I. Aggressive non-Hodgkin’s lymphomas. Oncology 55:189–217. https://doi.org/10.1159/000011855
doi: 10.1159/000011855
pubmed: 9560053
Kanesvaran R, Cordoba R, Maggiore R (2018) Immunotherapy in Older Adults With Advanced Cancers: Implications for Clinical Decision-Making and Future Research. Am Soc Clin Oncol Educ B 400–414 https://doi.org/10.1200/edbk_201435
Johnstone J, Parsons R, Botelho F et al (2017) T-Cell Phenotypes Predictive of Frailty and Mortality in Elderly Nursing Home Residents. J Am Geriatr Soc 65:153–159. https://doi.org/10.1111/jgs.14507
doi: 10.1111/jgs.14507
pubmed: 27775813
Daste A, Chakiba C, Domblides C et al (2016) Targeted therapy and elderly people: A review. Eur J Cancer 69:199–215. https://doi.org/10.1016/j.ejca.2016.10.005
Eisenhauer EA, Therasse P, Bogaerts J et al (2009) New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer 45:228–247. https://doi.org/10.1016/j.ejca.2008.10.026
doi: 10.1016/j.ejca.2008.10.026
pubmed: 19097774
Cancer Therapy Evaluation Program (CTEP) (2017) Common Terminology Criteria for Adverse Events (CTCAE).v.5.0 [5x7]. Cancer Ther Eval Progr 155
Garrido-Laguna I, Janku F, Vaklavas C et al (2012) Validation of the Royal Marsden Hospital prognostic score in patients treated in the Phase I Clinical Trials Program at the MD Anderson Cancer Center. Cancer 118:1422–1428. https://doi.org/10.1002/cncr.26413
doi: 10.1002/cncr.26413
pubmed: 21823111
Templeton AJ, McNamara MG, Šeruga B et al (2014) Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis. J Natl Cancer Inst 106:dju124. https://doi.org/10.1093/jnci/dju124
Xue P, Kanai M, Mori Y et al (2014) Neutrophil-to-lymphocyte ratio for predicting palliative chemotherapy outcomes in advanced pancreatic cancer patients. J Natl Cancer Inst 106:406–415. https://doi.org/10.1093/jnci/dju124
doi: 10.1093/jnci/dju124
Ferrucci PF, Ascierto PA, Pigozzo J et al (2016) Baseline neutrophils and derived neutrophilto-lymphocyte ratio: Prognostic relevance in metastatic melanoma patients receiving ipilimumab. Ann Oncol 27:732–738. https://doi.org/10.1093/annonc/mdw016
doi: 10.1093/annonc/mdw016
pubmed: 26802161
Sacdalan DB, Lucero JA, Sacdalan DL (2018) Prognostic utility of baseline neutrophil-to-lymphocyte ratio in patients receiving immune checkpoint inhibitors: A review and meta-analysis. Onco Targets Ther 11:955–965. https://doi.org/10.2147/OTT.S153290
doi: 10.2147/OTT.S153290
pubmed: 29503570
pmcid: 5827677
Li B, Zhou P, Liu Y et al (2018) Platelet-to-lymphocyte ratio in advanced Cancer: Review and meta-analysis. Clin Chim Acta 483:48–56. https://doi.org/10.1016/j.cca.2018.04.023
Baldini C, Le Saux O, Helissey C et al (2018) Are phase I trials safe for older patients? J Geriatr Oncol 9:87–92. https://doi.org/10.1016/j.jgo.2017.08.012
Schwandt A, Harris PJ, Hunsberger S et al (2014) The role of age on dose-limiting toxicities in Phase i dose-escalation trials. Clin Cancer Res 20:4768–4775. https://doi.org/10.1158/1078-0432.CCR-14-0866
doi: 10.1158/1078-0432.CCR-14-0866
pubmed: 25028396
pmcid: 5207798
Extermann M, Overcash J, Lyman GH et al (1998) Comorbidity and functional status are independent in older cancer patients. J Clin Oncol Off J Am Soc Clin Oncol 16:1582–1587. https://doi.org/10.1200/JCO.1998.16.4.1582
doi: 10.1200/JCO.1998.16.4.1582
Caillet P, Canoui-Poitrine F, Vouriot J et al (2011) Comprehensive geriatric assessment in the decision-making process in elderly patients with cancer: ELCAPA study. J Clin Oncol Off J Am Soc Clin Oncol 29:3636–3642. https://doi.org/10.1200/JCO.2010.31.0664
doi: 10.1200/JCO.2010.31.0664
Liu R, Gomes A, Ao G et al (2020) 592P A predictive score of antitumour activity of novel agents in cancer patients treated in early phase studies. Ann Oncol 31:S497. https://doi.org/10.1016/j.annonc.2020.08.706
doi: 10.1016/j.annonc.2020.08.706
Denson AC, Mahipal A (2014) Participation of the elderly population in clinical trials: Barriers and solutions. Cancer Control 21:209–214. https://doi.org/10.1177/107327481402100305
doi: 10.1177/107327481402100305
pubmed: 24955704
Belgioia L, Desideri I, Errico A et al (2019) Safety and efficacy of combined radiotherapy, immunotherapy and targeted agents in elderly patients: A literature review. Crit Rev Oncol Hematol 133:163–170. https://doi.org/10.1016/j.critrevonc.2018.11.009
doi: 10.1016/j.critrevonc.2018.11.009
pubmed: 30661652
Hurria A, Browner IS, Cohen HJ et al (2012) Senior adult oncology: Clinical practice guidelines in oncology. JNCCN J Natl Compr Cancer Netw 10:162–209. https://doi.org/10.6004/jnccn.2012.0019
doi: 10.6004/jnccn.2012.0019